Clinical data | |
---|---|
Trade names | Dolobid |
AHFS/Drugs.com | Monograph |
MedlinePlus | a684037 |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 80-90% |
Protein binding | >99% |
Metabolism | Hepatic |
Elimination half-life | 8 to 12 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.040.925 |
Chemical and physical data | |
Formula | C13H8F2O3 |
Molar mass | 250.201 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Diflunisal is a salicylic acid derivative with analgesic and anti-inflammatory activity.[2] It was developed by Merck Sharp & Dohme in 1971, as MK647, after showing promise in a research project studying more potent chemical analogs of aspirin.[3] It was first sold under the brand name Dolobid, marketed by Merck & Co., but generic versions are now widely available. It is classed as a nonsteroidal anti-inflammatory drug (NSAID) and is available in 250 mg and 500 mg tablets.